prof. MUDr. Jiří Mayer, CSc.
Department head, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 3643, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 1618
2013
-
Mutační analýza genu NOTCH1 u pacientů s chronickou lymfocytární leukemií
Year: 2013, type: Conference abstract
-
Nemoc chladových aglutininů nereagující na léčbu glukokortikoidy a na léčbu rituximabem. Jaký postup zvolit pro III. linii léčby? Popis případu a přehled literatury
Vnitřní lékařství, year: 2013, volume: 59, edition: 9
-
Normal hematopoietic stem cells can be detected in newly diagnosed chronic myeloid leukemia patients and leukemic stem cells can be detected in CML patients after therapy by a multi-technique approach using antigen CD26.
Year: 2013, type: Conference abstract
-
Nové perspektivy v patogenezi a diagnostice lymfomu z plášťových buněk (mantle cell lymfomu)
Onkologie, year: 2013, volume: 7, edition: 3
-
Nuromuscular toxicity of tyrosine kinase inhibitors in the therapy of patients with chronic myeloid leukemia
Year: 2013, type: Conference abstract
-
Ofatumumab added to dexamethasone in patients with relapsed of refractory chronic lymphocytc leukemia. Results from a phase II study of the czech leukemia study group for life
Year: 2013, type: Conference abstract
-
PET-CT dokumentovaný rychlý nástup léčebné odpovědi cyklofosfamidu, thalidomidu a dexametazonu u multicentrické formy Castlemanovy nemoci. Popis případu a přehled informací o léčbě
Vnitřní lékařství, year: 2013, volume: 59, edition: 4
-
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
Leukemia, year: 2013, volume: 27, edition: 9, DOI
-
Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
Clinical Cancer Research, year: 2013, volume: 19, edition: 9, DOI
-
Quantitative detection of an IDH2 mutation for minimal residual disease monitoring in acute myeloid leukemia patients and its comparison with mutations in the NPM1 gene
Leukemia & Lymphoma, year: 2013, volume: 54, edition: 4, DOI